QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report “Continuous Blood Purification Device- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Continuous Blood Purification Device market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Continuous Blood Purification Device was estimated to be worth US$ 2201 million in 2025 and is projected to reach US$ 3772 million, growing at a CAGR of 8.0% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5786058/continuous-blood-purification-device
1. Continuous Blood Purification Device Product Introduction
In 2025, global Continuous Blood Purification Device production reached approximately 55 k units with an average global market price of around k US$14 per unit. Single-line annual production capacity averages 2,600 units with a gross margin of approximately 25-30%. The upstream of Continuous Blood Purification Device primarily includes core components such as blood purification equipment hosts, filters, replacement fluids, dialysate, tubing systems, monitoring sensors, and control systems, among which high-precision filters and specialized replacement fluids have high technical barriers and are mainly concentrated in technologically developed regions such as Europe, America, and Japan; in downstream applications, hospitals account for approximately 85%, clinics for 5%, dialysis centers for 8%, home care for 1%, and others (such as emergency centers) for 1%. With the increase in the global number of critically ill patients, the acceleration of aging processes, and medical technological advancements making continuous blood purification safer and more feasible, the market demand for Continuous Blood Purification Device is showing a significant growth trend, especially against the backdrop of increasing demand for treating critically ill patients in departments such as ICU, nephrology, and emergency medicine, where continuous blood purification is gradually transitioning from a supplementary option to traditional intermittent dialysis to an important treatment choice. The market for Continuous Blood Purification Device possesses enormous development potential, not only reflected in the equipment sales itself but also including multiple dimensions such as supporting consumables, remote monitoring services, professional training, and business model innovations combined with medical insurance policies. Particularly in high-end medical fields in developed countries and emerging markets, providing intelligent, efficient, and easy-to-operate continuous blood purification solutions will obtain considerable market share and long-term stable returns.
Continuous Renal Replacement Therapy (CRRT) represents a sophisticated form of extracorporeal blood purification designed to provide sustained, around-the-clock renal replacement for patients with acute or chronic kidney failure. Unlike conventional hemodialysis machines that generate dialysate and replacement fluids online, CRRT systems utilize commercially prepared, pre-mixed solutions to deliver continuous therapies such as hemodialysis, hemofiltration, and hemodiafiltration. These systems are engineered for extended operation—typically 24 hours or nearly continuous—employing precise fluid management technologies that carefully control ultrafiltration rates, solute clearance, and electrolyte balance while maintaining hemodynamic stability in critically ill patients. The technological architecture incorporates advanced monitoring capabilities that track multiple parameters in real-time, including transmembrane pressure, blood temperature, and circuit integrity, with automated safety features that respond to deviations from preset parameters. CRRT machines are designed with modular components that can be customized based on specific patient needs, allowing healthcare providers to tailor treatment intensity and modality according to the clinical condition. By operating continuously rather than intermittently, these systems more closely mimic natural kidney function, providing gradual solute and fluid removal that is better tolerated by hemodynamically unstable patients. The comprehensive approach encompasses not just the hardware but also includes specialized training for clinical staff, comprehensive technical support, and meticulous management of fluid and solution supplies to ensure safe and effective therapy delivery.
Figure1: Continuous Blood Purification Device Product Picture
Based on or includes research from QYResearch:
2. Leading Manufacturer in the industry
1) Fresenius Medical Care
Fresenius Medical Care is a global leading provider of products and services for the diagnosis and treatment of kidney diseases, focusing on delivering comprehensive renal replacement therapy solutions for patients with chronic and acute renal failure. Its core businesses cover hemodialysis, peritoneal dialysis, and related consumables, equipment, and dialysis clinic network operations. Through advanced therapies such as high-volume hemodiafiltration (HDF), it helps millions of patients achieve toxin removal, fluid balance, and improved quality of life. At the same time, in the field of acute kidney injury, it provides Continuous Kidney Replacement Therapy (CKRT/CRRT) and has further expanded into extracorporeal blood purification technologies including therapeutic plasma exchange, cytokine adsorption, and low-flow extracorporeal carbon dioxide removal, supporting multi-organ support needs in intensive care units. The company is committed to enhancing overall treatment effectiveness and patient outcomes through innovative products, digital connectivity, and comprehensive clinical support.
In the field of Hydrogen Fuel Cell EngineContinuous Blood Purification Device, Fresenius Medical Care offers a multi-tiered product portfolio ranging from basic models to fully featured systems. Basic continuous blood purification devices are centered on reliable, classic therapy modes, supporting standard Continuous Veno-Venous Hemofiltration (CVVH), Continuous Veno-Venous Hemodialysis (CVVHD), and Continuous Veno-Venous Hemodiafiltration (CVVHDF). They are equipped with simplified user interfaces and basic fluid balance management functions, making them suitable for routine continuous clearance needs in patients with acute kidney injury. Professional continuous blood purification devices integrate regional citrate anticoagulation (Ci-Ca®) technology, significantly reducing bleeding risk and extending filter lifespan to more than 72 hours, while also supporting precise thermal balance control, automatic pump speed adjustment, and intelligent alarm systems. These features optimize treatment stability and safety for patients at high bleeding risk or with complex critical conditions. Fully featured continuous blood purification devices, represented by multiFiltratePRO, serve as multi-modal, team-oriented platforms. In addition to covering all CRRT modalities mentioned above, they are compatible with therapeutic plasma exchange (TPE), adsorbers (such as CytoSorb® for cytokine removal), and low-flow ECCO2R applications. They are equipped with large adjustable touchscreens, HL7 data connectivity, integrated heaters, automated plasma volume calculation, and comprehensive user guidance and support functions, enabling comprehensive and individualized extracorporeal purification support for ICU patients ranging from acute kidney injury to multi-organ failure, significantly improving clinical workflow efficiency, treatment predictability, and resource utilization.
The multiFiltratePRO from Fresenius Medical Care is an advanced continuous blood purification device designed specifically for intensive care unit (ICU) patients, primarily used for Continuous Renal Replacement Therapy (CRRT), and suitable for patients weighing more than 40 kg with acute kidney injury or multi-organ failure. Through an extracorporeal blood circulation system, it controls and monitors the blood purification process and supports multiple therapy modes, including Continuous Veno-Venous Hemofiltration (CVVH), Continuous Veno-Venous Hemodiafiltration (CVVHDF), and Continuous Veno-Venous Hemodialysis (CVVHD), to continuously replace renal function, remove toxins, and regulate fluid and electrolyte balance. The device is equipped with a large adjustable touchscreen interface that is easy to operate and minimizes user interaction. It integrates Ci-Ca® regional citrate anticoagulation technology to reduce bleeding risk and enhance treatment safety, and features intelligent alarm systems, automatic pump speed adjustment, and precise fluid management functions to ensure treatment stability and patient safety. In addition, it is compatible with multiple filters and tubing sets, providing flexible therapy options, and its modular design facilitates maintenance and upgrades, thereby improving overall clinical practice efficiency and therapeutic outcomes for ICU teams.
2) Baxter
Baxter is a global leading provider of acute care and kidney disease treatment solutions, with its core business focused on delivering comprehensive renal replacement therapies for patients with acute and chronic renal failure, including Continuous Renal Replacement Therapy (CRRT), Hemodialysis (HD), Peritoneal Dialysis (PD), as well as related consumables, dialysis solutions, filters, and dedicated systems. Through innovative extracorporeal blood purification technologies, Baxter helps critically ill patients achieve toxin removal, fluid overload management, electrolyte balance regulation, and inflammatory mediator removal, supporting full-spectrum care from Acute Kidney Injury (AKI) to end-stage renal disease. Its solutions further extend to sepsis management, Therapeutic Plasma Exchange (TPE), Hemoperfusion (HP), and Extracorporeal Carbon Dioxide Removal (ECCO₂R), and are committed to improving ICU treatment effectiveness, patient survival, and resource optimization through digital tools, precision therapies, and comprehensive clinical support.
In the field of Hydrogen Fuel Cell EngineContinuous Blood Purification Device, Baxter offers a multi-tier CRRT product portfolio ranging from basic to fully featured systems. Basic continuous blood purification devices are centered on the Prismaflex platform, supporting standard modalities such as Slow Continuous Ultrafiltration (SCUF), Continuous Veno-Venous Hemofiltration (CVVH), Continuous Veno-Venous Hemodialysis (CVVHD), and Continuous Veno-Venous Hemodiafiltration (CVVHDF). These systems are equipped with precision pumps and high-accuracy scales to achieve ±1% fluid balance accuracy, the TRUEVUE intelligent alarm system, and automatic effluent drain functions, making them suitable for continuous solute clearance and fluid management in routine acute kidney injury patients. Professional continuous blood purification devices further optimize anticoagulation strategies and treatment stability based on Prismaflex, supporting heparin or regional citrate anticoagulation, oXiris filters for cytokine and endotoxin removal, pre-rinse and automatic blood return functions, and providing extended filter life and reduced complication risks for patients with high bleeding risk, sepsis, or complex critical conditions. Fully featured continuous blood purification devices, represented by PrisMax and PrisMax 2, serve as next-generation multi-organ support platforms. In addition to covering all CRRT modalities and TPE/HP, they integrate ECCO₂R applications such as PrismaLung+ for hypercapnia management, enable combined CRRT and sepsis blood purification through the Oxiris 3-in-1 filter, incorporate TherMax blood temperature control, automatic drainage, and enhanced touchscreen interfaces, and support treatment without weight limitations from neonates to adults. These systems reduce manual intervention, improve dose delivery accuracy and user experience, significantly lower ICU operational burden, training requirements, and therapy interruption time, and provide comprehensive, personalized extracorporeal life support for patients with multi-organ failure.
Prismaflex from Baxter is an advanced Hydrogen Fuel Cell EngineContinuous Blood Purification Device designed specifically for intensive care unit (ICU) use, primarily for Continuous Renal Replacement Therapy (CRRT), and is suitable for patients ranging from 2 kg neonates to adults with no upper weight limit who suffer from acute kidney injury, fluid overload, multi-organ failure, or sepsis. Through an extracorporeal blood circulation system, it enables continuous toxin removal, fluid balance regulation, and electrolyte stabilization, and supports multiple therapy modalities including Slow Continuous Ultrafiltration (SCUF), Continuous Veno-Venous Hemofiltration (CVVH), Continuous Veno-Venous Hemodialysis (CVVHD), Continuous Veno-Venous Hemodiafiltration (CVVHDF), Therapeutic Plasma Exchange (TPE), and Hemoperfusion (HP), allowing seamless modality switching to meet dynamic patient needs. The device is equipped with an 8-inch color touchscreen and an intuitive graphical user interface that minimizes operational steps, with guided setup and loading completed within minutes. It integrates five precision pumps and five high-accuracy electronic scales to achieve fluid balance accuracy of ±1% or 30 g/h, features the proprietary TRUEVUE intelligent alarm system that displays only critical alerts with clear resolution guidance, and includes Auto Effluent Drain functionality to reduce manual handling. The system supports pre-rinse, automatic blood return, therapy initiation after patient connection, and anticoagulation options with heparin or regional citrate, enhancing treatment safety and extending filter life. It is compatible with dedicated Prismaflex tubing sets and multiple filters such as HF20, M60, M100, and oXiris, ensuring flexibility and compatibility, significantly reducing ICU nursing workload and training time, and providing critically ill patients with reliable 24-hour continuous life support to improve clinical efficacy and patient outcomes.
3) NorrDia
NorrDia is a global medical solutions provider focused on renal and acute care therapies. Its core business is dedicated to delivering reliable, simple, and cost-effective Continuous Renal Replacement Therapy (CRRT), hemodialysis, and related consumables and systems for patients with acute and chronic renal failure. By integrating more than 50 years of kidney care experience and technical expertise derived from the legacy of Gambro, Baxter, and Nikkiso, NorrDia delivers high-quality extracorporeal blood purification support to intensive care units and dialysis centers, covering acute kidney injury (AKI), multi-organ failure, sepsis management, and extracorporeal organ support applications such as cytokine adsorption and ECCO₂R. The company emphasizes ease of use, treatment reliability, improved patient outcomes, and cost-effectiveness optimization, while continuously strengthening its comprehensive product portfolio and global market influence in acute and chronic renal therapies through acquisitions and product expansion.
In the field of Hydrogen Fuel Cell EngineContinuous Blood Purification Device, NorrDia takes the Aquarius™ Systems as its core platform and provides modular CRRT solutions ranging from basic to fully featured configurations. Basic continuous blood purification devices are built on the Aquarius™ System combined with Platinum Software and support standard CRRT therapies, including Continuous Veno-Venous Hemofiltration (CVVH), Continuous Veno-Venous Hemodialysis (CVVHD), and Continuous Veno-Venous Hemodiafiltration (CVVHDF). These systems are equipped with blood pumps, fluid pumps, scales, integrated safety protections, user-friendly interfaces, Total Fluid Loss Management (TFL) fluid compensation functions, actual dose display, and rapid alarm resolution tools. They are suitable for routine acute kidney injury treatment and fluid management in adult and low-weight patients with a minimum body weight of 20 kg, offering heparin-based anticoagulation options to ensure operational simplicity and treatment predictability. Professional continuous blood purification devices are upgraded to the Aquarius™ System with Aquarius+ Software, integrating Regional Citrate Anticoagulation (RCA) functionality. These systems support flexible switching between heparin and citrate anticoagulation, personalized CRRT adjustments to accommodate patient metabolic changes, extended filter life, and reduced bleeding and transfusion requirements, thereby optimizing safety, stability, and filter utilization efficiency for critically ill patients with high bleeding risk or metabolic instability. Fully featured continuous blood purification devices further expand Aquarius+ Software variants, including dedicated low-volume RCA configurations. In addition to covering all CRRT modes as well as Therapeutic Plasma Exchange (TPE) and Hemoperfusion (HP), they are compatible with acute blood purification consumables such as third-generation Efferon® LPS adsorbers for endotoxin and cytokine removal in sepsis and septic shock, and ProLUNG® systems enabling ECCO₂R-based lung-protective strategies. These systems support multi-organ support therapies for patients ranging from adults to low-weight populations and adopt modular designs, dedicated low-volume kits such as Aqualine S RCA, and single-use sets combining AQUAMAX filters to achieve highly flexible personalized treatment, reduce manual intervention, and improve ICU clinical efficiency and patient survival rates.
The Aquarius™ System from NorrDia is an advanced Hydrogen Fuel Cell EngineContinuous Blood Purification Device specifically designed for Continuous Renal Replacement Therapy (CRRT). It is primarily used for the treatment of acute kidney injury, fluid overload, or multi-organ failure in adult and low-weight patients with a minimum body weight of 20 kg. Through an extracorporeal blood circulation system, it enables continuous toxin removal, fluid balance regulation, and electrolyte management. The system supports multiple therapy modes, including standard CRRT modalities such as Continuous Veno-Venous Hemofiltration (CVVH), Continuous Veno-Venous Hemodialysis (CVVHD), and Continuous Veno-Venous Hemodiafiltration (CVVHDF), and extends to Therapeutic Plasma Exchange (TPE) and Hemoperfusion (HP). It is compatible with single-use sets integrating AQUAMAX filters and tubing, as well as dedicated low-volume kits to accommodate smaller patients. The device supports heparin-based anticoagulation or Regional Citrate Anticoagulation (RCA) configurations enabled through Aquarius+ Software, enhancing treatment safety and extending filter life. Its modular software options include Platinum Software for standard CRRT operations and Aquarius+ Software variants for optimized RCA monitoring and automated adjustments, ensuring precise fluid management and responsive alarm handling. A distinguishing feature is its compatibility with acute blood purification consumables, such as third-generation blood adsorbers for cytokine removal in sepsis and septic shock. Overall, the system emphasizes user-friendly design, flexible compatibility, and clinical reliability, significantly improving ICU team efficiency and patient outcomes.
4) Bbraun
B. Braun is a globally leading provider of medical technology and solutions, with core businesses covering acute care, intensive care, and renal disease treatment. It focuses on delivering comprehensive extracorporeal blood purification therapies for patients with chronic kidney disease and acute kidney injury, including chronic hemodialysis, Continuous Renal Replacement Therapy (CRRT), Therapeutic Plasma Exchange (TPE), and plasma adsorption. Through innovative portfolios of machines, consumables, filters, tubing sets, and dialysis fluids, it supports clinical needs ranging from acute renal failure to multi-organ dysfunction. The company emphasizes precise fluid management, high safety standards, optimized anticoagulation strategies, and user-friendly design to reduce ICU nursing burden, improve treatment accuracy, extend filter life, and enhance patient outcomes, while further expanding into multi-organ support platforms such as Extracorporeal Carbon Dioxide Removal (ECCO₂R) and adsorber integration, and is committed to advancing standardization and efficiency in the acute blood purification field through intelligent and modular technologies.
In the field of Continuous Blood Purification Device, B. Braun offers a tiered CRRT product portfolio ranging from basic to fully featured systems. Basic continuous blood purification devices are centered on the Diapact® CRRT platform and support standard continuous modalities such as Slow Continuous Ultrafiltration (SCUF), Continuous Veno-Venous Hemofiltration (CVVH), Continuous Veno-Venous Hemodialysis/High-Flux Dialysis (CVVHD/HFD), and Continuous Veno-Venous Hemodiafiltration (CVVHDF). They are equipped with a single load cell to achieve high-precision fluid balance (±30 ml/h), an online fluid heater adjustable from 20–39°C to maintain body temperature stability, heparin pump integration software, HomeoSAFE intelligent safety software, and integrated alarm and pressure monitoring systems. These systems are suitable for continuous solute clearance and fluid management in routine acute kidney injury patients, offering pre- and post-dilution options as well as intermittent high-flow dialysis capability to ensure ease of operation and hemodynamic stability. Professional continuous blood purification devices further optimize Diapact® or transition to the OMNI® platform, supporting flexible switching between heparin and Regional Citrate Anticoagulation (RCA), automatic pump speed adjustment, precise dose delivery, and extended filter life averaging more than 22–33 hours. These features enhance treatment safety, reduce downtime, and lower complication risks for critically ill patients with high bleeding risk, metabolic instability, or complex anticoagulation requirements. Fully featured continuous blood purification devices are represented by the OMNI® acute blood purification system, which serves as a new-generation multi-organ support platform. In addition to covering all CRRT modalities (CVVH, CVVHD, CVVHDF) and TPE, it integrates ECCO₂R (such as OMNIset ECCO2R for CO₂ removal), OMNIset Plus compatibility with external adsorbers or cartridges for cytokine or endotoxin adsorption, automatic priming (approximately 10 minutes for CRRT), plug-and-play OMNIset® disposables, a step-by-step intuitive touchscreen interface, battery backup of up to 30 minutes, lightweight and mobile design (approximately 62 kg), and low downtime rates (alarm-related downtime of only 5.9%). These features enable personalized, multi-modality extracorporeal purification support for adult and critically ill patients, significantly reducing manual intervention, training requirements, and therapy interruption time, and providing a comprehensive, efficient, and reliable life support platform for ICU patients with multi-organ failure.
B. Braun’s Diapact® CRRT is an integrated Continuous Blood Purification Device designed specifically for intensive care unit (ICU) use, intended for Continuous Renal Replacement Therapy (CRRT) and intermittent renal replacement therapies. It is suitable for adult patients with acute renal failure, multi-organ failure, or fluid overload. Through an extracorporeal blood circulation system, it enables high-flow toxin removal, fluid balance regulation, electrolyte stabilization, and inflammatory mediator removal. The system supports multiple treatment modalities, including Continuous Veno-Venous Hemofiltration (CVVH), Continuous Veno-Venous Hemodialysis/High-Flux Dialysis (CVVHD/HFD), Continuous Veno-Venous Hemodiafiltration (CVVHDF), and Slow Continuous Ultrafiltration (SCUF), and can handle high flow rates to accommodate intermittent therapy requirements. The device is equipped with a single load cell for precise fluid monitoring to ensure ±30 ml/h accuracy, an online fluid heater adjustable from 20–39°C to maintain patient body temperature stability, a blood pump (MP1) and heparin pump (Perfusor® for Diapact) to support heparin anticoagulation options, and standard dialysis blood circuits compatible with multiple filters and tubing sets. Utilizing the unique HomeoSAFE software approach, it provides a user-friendly interface, automatic pump speed adjustment, intelligent alarm systems, and safety features such as air detection and pressure monitoring, reducing complication risks and extending filter life. Overall, the system emphasizes ease of operation and clinical reliability by integrating all acute blood purification functions into a single platform, significantly improving ICU team efficiency, patient safety, and clinical outcomes.
3. Key Market Trends, Opportunity, Drivers and Restraints
1) Market Trends
The global Hydrogen Fuel Cell EngineContinuous Blood Purification Device industry is transitioning from the manufacturing of standalone therapeutic hardware toward deep integration of “intelligence, systems, and services.” In the field of critical care, demand is growing for continuous blood purification (CBP) systems capable of delivering bedside, continuous, and hemodynamically stable therapy, particularly in intensive care scenarios such as acute kidney injury and sepsis. The core of technological innovation lies in enhancing intelligence and integration levels. For example, devices are increasingly integrating AI-based real-time monitoring, remote operation and maintenance, and adaptive adjustment functions to enable precise early warning and personalized management throughout the treatment process. At the same time, leading companies are committed to developing next-generation systems with breakthrough functionalities. For instance, Fresenius Medical Care has developed a novel dialysis system designed to prevent blood coagulation without the use of anticoagulants, which has received the “Breakthrough Device” designation from the U.S. Food and Drug Administration (FDA). This represents a frontier trend in technological development toward improved patient safety and greater treatment convenience.
5) Opportunities
Industry development opportunities mainly stem from substantial unmet clinical demand, the wave of domestic substitution, and the expansion of treatment scenarios. Globally, the continuous increase in the number of patients with chronic kidney disease (CKD) and acute kidney injury (AKI) constitutes a long-term driving force for market growth. In emerging markets such as China, there is a significant gap in service capacity at primary healthcare institutions, providing broad penetration space for more cost-effective domestically produced devices. Domestic substitution represents one of the most clearly defined opportunities at present. Leading Chinese enterprises, represented by Chongqing Sanwaishan, are gradually overcoming production and technological barriers, with the domestic market share of their Hydrogen Fuel Cell EngineContinuous Blood Purification Device products steadily increasing to nearly 30%. In addition, treatment models are extending from hospital intensive care units (ICUs) to areas such as home dialysis and emergency medical rescue, giving rise to demand for high-performance, intelligent, and multi-modality blood purification systems.
6) Challenges
The core challenges facing the industry are reflected across clinical, economic, and systemic dimensions. Clinically, physicians’ long-established operational habits and treatment paradigms formed through prolonged use of foreign brands constitute strong brand barriers, leading to concerns regarding the operational stability and complication control performance of domestically produced devices. Economic pressure is particularly pronounced, with high equipment acquisition costs and treatment expenses representing common obstacles. In developing countries, the lack of medical insurance reimbursement support makes “high-cost treatments” difficult to popularize. Systemic challenges include the uneven distribution of medical resources, with many regions facing severe shortages of nephrology specialists and professionally trained operators. In addition, globally stringent regulatory approval processes, ongoing training requirements for healthcare personnel, and price pressures arising from volume-based procurement policies in certain countries or regions further increase the complexity and uncertainty of market expansion.
7) Industry Entry Barriers
This industry features extremely high technological and market entry barriers. The barriers to technological research and development are exceptionally high, involving the development of core components such as high-precision sensors, online monitoring algorithms, and hollow-fiber dialysis membranes. These technologies have long been monopolized by international giants through intensive patent portfolios, requiring new entrants to overcome lengthy R&D cycles and massive capital investment. Production process and supply chain barriers are equally critical. The process requirements from pilot-scale testing to large-scale mass production are stringent, and core manufacturing equipment (such as dialysis membrane spinning nozzles) has long relied on imports, making stable, high-yield mass production itself a major challenge. Market and brand barriers are deeply entrenched, as existing multinational companies such as Fresenius, B. Braun, and Nikkiso have established long-term, stable partnerships with top-tier hospitals worldwide and occupy the majority of market share, making it difficult for new brands to gain clinical trust in the short term. Finally, regulatory barriers must not be underestimated. Market entry in any major region (such as the United States, the European Union, or China) requires passing rigorous, time-consuming, and costly registration and approval processes, posing severe challenges to enterprises’ regulatory capabilities and time costs.
4. Supply Chain Analysis
1) Upstream Market
a) Functional Membrane Materials
Functional membrane materials, as upstream raw materials in the Continuous Blood Purification Device industry chain, mainly include polysulfone and polyethersulfone. They are the core components used in the manufacture of CRRT filters and dialyzers and directly determine toxin removal efficiency, biocompatibility, and filter lifespan. Fresenius Medical Care uses a Fresenius Polysulfone membrane developed specifically for CKRT in its Ultraflux AV filters. This membrane allows plasma proteins, including immunoglobulins such as IgM and lipoproteins, to pass through, enabling efficient toxin removal and extracorporeal purification support. At the same time, its FX series dialyzers adopt the Helixone membrane, which is manufactured based on polysulfone using Nano-Controlled Spinning Technology (NCS™), forming a highly defined pore size structure and smooth cylindrical inner pores that reduce molecular transport resistance and enhance middle-molecule toxin clearance while maintaining low albumin loss and excellent endotoxin retention properties. In the FX CorAL dialyzers, this membrane is further optimized into the Helixone hydro membrane by adding PVP to the precipitation solution to form a blood-side-enriched hydrophilic layer, reducing protein adsorption and improving blood compatibility. Baxter provides polysulfone-based filters (such as the HF series) and polyarylethersulfone (PAES) membrane options in its Prismaflex system filter sets. For example, the HF1000/HF1400 sets adopt PAES membranes to support toxin adsorption and removal across multiple CRRT modalities, while the AN69 membrane provides additional removal of high-molecular-weight toxins such as myoglobin and β2-microglobulin in acute kidney injury patients through a unique adsorption mechanism, ensuring stable membrane performance. B. Braun uses polysulfone and polyethersulfone membranes in the OMNI system and Diapact CRRT, for example, Omnifilter employs polyethersulfone or polysulfone membranes to support efficient uremic toxin elimination under CVVH, CVVHD, and CVVHDF modes, combined with high packing density and micro-ripple structures to enhance air removal efficiency and dialysate flow uniformity. Meanwhile, Diacap Ultra, used as a bacteria and pyrogen filter, adopts high-grade polysulfone fibers to enable the preparation of ultrapure dialysate. These upstream membrane materials, through blending with hydrophilic copolymers such as PVP or surface modification, enhance the blood compatibility of hydrophobic substrates, reduce complement activation and leukocyte reduction, and support steam sterilization or gamma irradiation, ensuring that CRRT devices deliver continuous and reliable extracorporeal blood purification in ICU environments and support toxin diffusion, convective clearance, electrolyte balance, and fluid management for patients ranging from acute kidney injury to multi-organ failure.
b) Adsorptive Materials
Adsorptive materials, as upstream raw materials in the Continuous Blood Purification Device industry chain, mainly include activated carbon, polymer resins, and immunoadsorbents. They are the core components used in the manufacture of hemoperfusion cartridges and adsorption columns and directly determine the adsorption efficiency, selectivity, and biocompatibility for middle-molecular-weight toxins, cytokines, endotoxins, bilirubin, and other substances. Fresenius Medical Care incorporates CytoSorb as a featured blood purification therapy within its critical care platform. This adsorber consists of highly porous polymer beads that provide a large surface area for adsorption, restrict the entry of larger substances through pore size distribution, and effectively target low- and middle-molecular-weight substances such as cytokines, bilirubin, and myoglobin for adsorption and removal as blood passes through the device, supporting extracorporeal purification for ICU patients with multi-organ failure. Baxter’s oXiris filter adopts an AN69 membrane with polyethyleneimine coating and sulfonic acid groups, enabling negatively charged endotoxin adsorption as well as cytokine adsorption, offering adsorption capabilities for inflammatory mediators similar to CytoSorb and being compatible with Prismaflex and PrisMax systems for combined CRRT and hemoperfusion to remove toxins and inflammatory mediators. NorrDia supports the third-generation Efferon LPS adsorber, which targets endotoxin and cytokine removal in sepsis and septic shock and enables extended applications on the Aquarius system, providing dedicated adsorption consumables for multi-organ support. Toraymyxin uses polymyxin B covalently immobilized on polystyrene-based fibers as a ligand to selectively adsorb endotoxins for direct hemoperfusion in sepsis patients, enhancing middle-molecule toxin clearance when combined with CRRT. Traditional activated carbon–based adsorption materials improve biocompatibility through coatings and are used to adsorb lipophilic and small-molecule toxins, while modern polymer resins such as the Amberlite series achieve reversible binding through polar and nonpolar interactions and are suitable for drug overdose and lipophilic toxin removal. Immunoadsorbents, through specific ligands such as protein A or polymyxin B, target pathogenic factors to provide selective adsorption mechanisms, reducing nonspecific binding and improving safety. These upstream adsorption materials, through surface modification, coatings, and molecular design, optimize blood compatibility, reduce platelet activation and complement activation, and support seamless integration with CRRT devices to enable continuous extracorporeal blood purification from acute kidney injury to sepsis and multi-organ failure, significantly improving treatment stability and patient outcomes.
c) Auxiliary Materials
Auxiliary materials, as upstream raw materials in the Continuous Blood Purification Device industry chain, mainly include medical-grade polyvinyl chloride (PVC) blood tubing, silicone components, and biocompatible coatings for anticoagulation. They are the core materials used to construct extracorporeal circulation tubing, pump segments, and connection components and directly determine blood compatibility, flexibility, pressure resistance, anticoagulation performance, and overall safety. Fresenius Medical Care uses medical-grade PVC materials to manufacture blood tubing in the multiFiltratePRO system and related CRRT tubing sets, ensuring flexibility and kink resistance, while certain hydraulic and dialysate tubing lines use peroxide-cured silicone components. However, due to potential risks of NDL-PCBA and NDL-PCB leaching, the company has updated affected machines and replaced them with platinum-catalyzed silicone tubing to enhance biocompatibility and safety, and has obtained FDA Breakthrough Device designation for the Endexo surface-modified polymer coating, which reduces thrombosis risk by blocking platelet and protein adhesion and improves the biocompatibility of dialysis systems without requiring patients to take anticoagulant medications. Baxter extensively uses DEHP-free PVC tubing as fluid pathway materials in the ST Set tubing of the Prismaflex and PrisMax systems, providing flexibility, durability, and kink resistance. While some product codes use DEHP-plasticized PVC, the company is committed to a full transition to DEHP-free IV containers and tubing assemblies to ensure long-term safety, and integrates biocompatible coatings in extended applications such as the oXiris filter to support endotoxin and cytokine adsorption. B. Braun uses medical-grade PVC and silicone tubing components in the preassembled tubing sets of the Diapact CRRT and OMNI systems, ensuring sterility, pyrogen-free performance, and good biocompatibility, supporting continuous and intermittent therapies as well as plasma exchange. Standard dialysis-type blood circuit systems combined with manifolds provide smooth fluid pathways and efficient air removal, while overall safety is optimized through HomeoSAFE software. NorrDia’s Aquarius system tubing is compatible with dedicated low-volume kits and uses medical-grade PVC and silicone materials to construct blood circuits, supporting regional citrate anticoagulation configurations. These upstream auxiliary materials, through DEHP-free formulations, surface modification, and biocompatible coatings such as heparin or non-heparin passive coatings, enhance blood-contact surface compatibility, reduce platelet activation, complement activation, and thrombosis risk, support steam or gamma sterilization, and ensure that CRRT devices achieve continuous and reliable extracorporeal blood circulation, precise fluid delivery, and minimized complications in ICU environments, providing stable and individualized extracorporeal purification support for patients with acute kidney injury, multi-organ failure, and sepsis.
8) Midstream
a) Basic CRRT Equipment
Basic CRRT Equipment, also referred to as entry-level CRRT machines, are bedside devices primarily used to deliver the core functions of renal replacement therapy, with treatment modalities focused on meeting the most fundamental needs of fluid management and solute clearance for critically ill patients. Taking the basic model (M03110) of the Italian EquaSmart blood purification therapy system as an example, its core design centers on three peristaltic pumps (a blood pump, a replacement fluid pump, and a dialysate pump) together with a heparin pump. The standardized treatment modalities it can deliver include Slow Continuous Ultrafiltration (SCUF), Continuous Veno-Venous Hemodialysis (CVVHD), Continuous Veno-Venous Hemofiltration (CVVH/HF), Continuous Veno-Venous Hemodiafiltration (CVVHDF), as well as Plasma Exchange (PE) and Hemoperfusion (HP). The defining characteristics of this category of equipment are relatively straightforward operation and the ability to stably provide continuous renal replacement therapy for more than 24 hours, which is essential for maintaining internal homeostasis in critically ill patients. These systems represent the entry-level and mainstay equipment for CRRT treatment in intensive care units (ICUs) and nephrology wards. Their industry outlook is closely linked to clinical trends in the incidence of Acute Kidney Injury (AKI). As foundational devices for critical care support, their widespread deployment and adoption across hospitals at all levels, particularly in primary healthcare institutions, are key to enhancing overall emergency and critical care capabilities.
b) Professional CRRT Equipment
Professional CRRT Equipment, often referred to as specialized or advanced CRRT machines, integrate more sophisticated blood purification technology platforms on top of full basic treatment capabilities, with the objective of addressing multi-organ support and refractory critical illnesses. Again using the specialized model (M03145) of the EquaSmart system as a representative example, in addition to all the functions of the basic configuration, it further provides advanced treatment modalities such as Selective Plasma Exchange (PPE), Plasma Diafiltration (PDF), Continuous Veno-Venous Hemofiltration combined with Plasma Adsorption (CVVHPA/CPFA), Continuous Veno-Venous Hemofiltration combined with Carbon Dioxide Removal (CVVH–CO₂ Removal), Double Filtration Plasmapheresis (DFPP), and Plasma Adsorption (PA). The distinguishing feature of this category lies in the breadth and depth of its therapeutic capabilities, enabling a single integrated extracorporeal circuit to perform a wide range of specialized treatments, from renal replacement to inflammatory mediator removal, immunoadsorption, and lipid apheresis. These capabilities address the complex clinical needs associated with sepsis and multi-organ failure. The industry outlook for Professional CRRT Equipment points toward increasingly precise and individualized critical care medicine, making such systems core assets for large medical centers and regional critical care hubs seeking to demonstrate comprehensive treatment capacity and advanced technical expertise.
c) Full-featured CRRT Equipment
Full-featured CRRT Equipment represents the current frontier of technological integration in the field. These systems go beyond the traditional scope of renal replacement therapy and are designed to establish integrated, intelligent treatment platforms encompassing multi-organ support. For example, the next-generation PrisMax system released by Vantive, the kidney care company planned to be spun off by Baxter, is designed to simultaneously support therapies for the kidneys and other vital organs by delivering multiple treatment modalities in parallel, thereby assisting in the management of acute kidney injury while providing organ function support for patients with multi-organ failure. Similarly, the PlasautoIQ molecular adsorption system developed by Asahi Kasei Corporation of Japan is a representative multifunctional blood purification device that supports Continuous Renal Replacement Therapy (CRRT), Plasma Exchange (PE), Double Filtration Plasmapheresis (DFPP), Plasma Adsorption (PA), and Leukocytapheresis (LCAP), among other modalities. The defining characteristics of this category include a high degree of system integration, diversified therapeutic capabilities, and outstanding clinical flexibility, often incorporating intelligent algorithms, localized and customized treatment parameters, and digitalized workflows designed to improve operational efficiency. The industry outlook for Full-featured CRRT Equipment is closely aligned with the trend in critical care medicine toward multidisciplinary collaboration and comprehensive life support, making these systems a core driving force behind the strategic transition of critical blood purification from “renal replacement” toward “whole-organ support.”
9) Downstream
a) Hospital
In Hospital applications, Continuous Blood Purification Devices are primarily deployed in intensive care units for the treatment of critically ill patients with acute kidney injury, multi-organ failure, and fluid overload. Through continuous extracorporeal hemofiltration, dialysis, and hemodiafiltration modalities, these systems remove toxins, regulate electrolyte balance, and maintain fluid stability. During the COVID-19 public health emergency, the U.S. Food and Drug Administration authorized the use of specific CRRT devices in hospitals to address the surge in acute renal function deterioration caused by severe illness. Fresenius Medical Care supplied acute care dialysis solutions to U.S. hospitals for use with the multiFiltrate PRO system to implement CRRT in hospital acute care settings, enabling emergency blood purification for COVID-19–related multi-organ failure patients. Baxter’s ST Set received FDA clearance for hospital use in treating patients with acute kidney injury, supporting multiple CRRT modalities including Slow Continuous Ultrafiltration, Continuous Veno-Venous Hemofiltration, and Continuous Veno-Venous Hemodiafiltration, helping remove toxins and manage volume overload while improving patient safety and therapeutic outcomes in acute hospital care. Cheshire Medical Center introduced CRRT machines in its hospital ICU and trained staff to provide life-saving continuous therapy for renal failure patients, delivering stable blood purification for critically ill cases unable to tolerate intermittent dialysis. The U.S. Department of Health and Human Services deployed portable renal dialysis machines to hospitals with high COVID-19 caseloads for ICU implementation of CRRT, supporting emergency management of acute kidney injury. Natchitoches Regional Medical Center implemented CRRT programs in its hospital ICU, providing 24-hour continuous dialysis for acutely ill patients with hypotension, managing poisoning, overdose, and severe electrolyte imbalance until renal function recovery.
b) Clinics
In Clinics applications, the use of Continuous Blood Purification Devices is mainly limited to transitional acute care or specific outpatient settings and is not considered standard practice, as CRRT is designed for hemodynamically unstable patients requiring continuous monitoring, whereas clinics typically manage chronic kidney disease or intermittent therapies. The Quanta Dialysis System supports high-dose hemodialysis and transitional care in post-acute clinics but does not designate CRRT modalities for routine outpatient use. Government documents and corporate communications emphasize that CRRT devices are infrequently deployed in Clinics, with FDA authorizations focusing on acute scenarios rather than routine outpatient environments. Clinics generally favor intermittent hemodialysis equipment to accommodate patient flow, while the continuous nature of CRRT requires specialized supervision and equipment maintenance that are not suitable for typical clinic operations. Corporate statements from Baxter and Fresenius position CRRT products for acute environments outside Clinics; when clinic use does occur, it is usually supported by specialized teams to manage complex cases, but official records do not highlight Clinics as a primary deployment setting.
c) Dialysis Center
In Dialysis Center applications, Continuous Blood Purification Devices are generally not considered a core practice, as Dialysis Centers primarily focus on intermittent hemodialysis for patients with chronic end-stage renal disease, whereas CRRT is designed for acute cases requiring continuous operation. Certain Dialysis Centers, such as those within Veterans Affairs Medical Center facilities, may be equipped with CRRT capabilities to support extended modalities like CVVH or CVVHD in conjunction with intermittent therapies, but this is limited to facilities with ICU-level capabilities. FDA and Centers for Medicare & Medicaid Services regulations for Dialysis Centers primarily cover standard hemodialysis equipment, with CRRT authorization focused on acute care needs rather than routine Dialysis Center operations. The Quanta system supports high-flow dialysis and ease of maintenance in center-based dialysis, but CRRT extensions are limited to acute care contexts and are not designated for Dialysis Center use. Corporate communications, such as those from Baxter, emphasize increased CRRT supply outside Dialysis Centers; when implemented within Dialysis Centers, CRRT is typically used as a supplemental measure to manage acute exacerbations, while official documentation underscores its priority deployment in Hospital environments.
The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.
The Continuous Blood Purification Device market is segmented as below:
By Company
Fresenius Medical Care
Baxter
Nikkiso
Bbraun
JMS
SB-KAWASUMI LABORATORIES
Infomed
Asahi Kasei
Medtronic
Chongqing SWS Hemodialysis Care
Zhuhai Jafron Biomedical
Beijing Weili Medical
Guangdong Biolight Meditech
Segment by Type
Basic CRRT Equipment
Professional CRRT Equipment
Full-featured CRRT Equipment
Segment by Application
Hospital
Clinics
Dialysis Center
Home Care
Others
Each chapter of the report provides detailed information for readers to further understand the Continuous Blood Purification Device market:
Chapter 1: Introduces the report scope of the Continuous Blood Purification Device report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of Continuous Blood Purification Device manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various Continuous Blood Purification Device market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of Continuous Blood Purification Device in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of Continuous Blood Purification Device in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Benefits of purchasing QYResearch report:
Competitive Analysis: QYResearch provides in-depth Continuous Blood Purification Device competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.
Industry Analysis: QYResearch provides Continuous Blood Purification Device comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.
and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.
Market Size: QYResearch provides Continuous Blood Purification Device market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.
Other relevant reports of QYResearch:
Global Continuous Blood Purification Device Market Research Report 2026
Global Continuous Blood Purification Device Market Outlook, In‑Depth Analysis & Forecast to 2032
Global Continuous Blood Purification Device Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
